Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234897 · ClinicalTrials.gov registry record · Phase 4
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
A Phase 4 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,938
- Enrollment target
NCT00234897 is a Phase 4 study that has completed, run by Abbott. The registered enrollment target is 1,938 participants.
The verdict
NCT00234897, a Phase 4 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,938 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment
Interventions
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,938 participants |
| Start Date | 2004-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234897
The ClinicalTrials.gov registry entry for NCT00234897 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,938 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.
NCT00234897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234897 about?
NCT00234897 is a clinical study titled "Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis". The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment
What is the current status of trial NCT00234897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,938 participants. The study started on 2004-08.
What interventions are being tested in trial NCT00234897?
The interventions under investigation include: adalimumab (DRUG).
Who is sponsoring clinical trial NCT00234897?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.